# Senti Biosciences

Source: https://onco.cc/companies/senti-biosciences/  
OnCo record `senti-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Senti Bio builds programmable 'gene circuits' into immune cells so they can tell cancer cells from healthy ones. Its lead product, SENTI-202, is an off-the-shelf CAR-NK cell therapy, made from donor natural killer cells, for acute myeloid leukaemia.

## Summary

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI), at 2 Corporate Drive in South San Francisco, uses a synthetic biology platform to engineer gene circuits into cell and gene therapies; its co-founder and chief executive is Tim Lu. The company says it is primarily focused on oncology cell therapy. Its lead product SENTI-202 is an off-the-shelf, logic-gated CAR-NK cell therapy directed at CD33 and/or FLT3 on leukaemia cells; the company has reported positive preliminary efficacy data, which were not read for this record. Its first registered cancer trial, NCT06325748 (SENTI-202-101), a phase 1 multicentre study of SENTI-202 in CD33- and/or FLT3-expressing haematological malignancies including acute myeloid leukaemia and myelodysplastic syndromes, was posted on ClinicalTrials.gov in March 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Senti Bio; Senti Biosciences Holdings, Inc.
- HQ: South San Francisco, CA
- Type: cell-therapy
- Website: https://www.sentibio.com/
- Ticker: SNTI

## Notes

- Ticker, exchange and business address confirmed from SEC EDGAR submissions data (CIK 1854270) on 29 October 2026. Founding year not stated on the pages read. How the logic gate works and the efficacy data were not read; 'logic gated' is the registry and company description. No private financing rows are recorded.

## Sources

- Official website: https://www.sentibio.com/
- SENTI-202 programme page: https://www.sentibio.com/research-pipeline/senti-202/
- SEC EDGAR filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001854270
- ClinicalTrials.gov: phase 1 trial of SENTI-202 (NCT06325748): https://clinicaltrials.gov/study/NCT06325748

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Logic-gated therapeutics (AND, NOT gates)](https://onco.cc/technologies/logic-gated-therapeutics/), [NK cell therapy and CAR-NK](https://onco.cc/technologies/nk-cell-therapy/)
- targets: [CD33](https://onco.cc/targets/cd33/), [FLT3](https://onco.cc/targets/flt3/)

---
JSON: https://onco.cc/api/v1/entities/senti-biosciences.json